| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.21311 |
| P698 | PubMed publication ID | 18232012 |
| P2093 | author name string | Paul van der Valk | |
| Bianca P Brink | |||
| Christa van den Berg | |||
| Christine D Dijkstra | |||
| Esther C W Breij | |||
| Lars Bö | |||
| Rianka Vloet | |||
| Riqiang Yan | |||
| Rob Veerhuis | |||
| P2860 | cites work | Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects | Q38747540 |
| Subpial demyelination in the cerebral cortex of multiple sclerosis patients | Q48233815 | ||
| Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. | Q48409149 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 16-25 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Homogeneity of active demyelinating lesions in established multiple sclerosis | |
| P478 | volume | 63 |
| Q48962920 | A second case of Marburg's variant of multiple sclerosis with vasculitis and extensive demyelination |
| Q36707237 | Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis |
| Q33745475 | Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid |
| Q36304844 | Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants |
| Q92719818 | Antibody signatures in patients with histopathologically defined multiple sclerosis patterns |
| Q26850135 | Antimicrobial peptides and complement in neonatal hypoxia-ischemia induced brain damage |
| Q36299698 | Apoptosis of oligodendrocytes in the central nervous system results in rapid focal demyelination |
| Q37743241 | Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. |
| Q38050398 | B cells and antibodies in multiple sclerosis pathogenesis and therapy |
| Q34808657 | B cells and multiple sclerosis |
| Q38212081 | B cells in MS and NMO: pathogenesis and therapy |
| Q64075120 | Bioinformatics Analyses Determined the Distinct CNS and Peripheral Surrogate Biomarker Candidates Between Two Mouse Models for Progressive Multiple Sclerosis |
| Q26865295 | Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system |
| Q42829214 | C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation |
| Q92712543 | Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis |
| Q33905233 | Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1. |
| Q35720710 | Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? |
| Q36218017 | Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. |
| Q41332646 | Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus |
| Q33722349 | Complement activation in multiple sclerosis plaques: an immunohistochemical analysis |
| Q37336914 | Complement in multiple sclerosis: its role in disease and potential as a biomarker. |
| Q100416128 | Complement in neurological disorders and emerging complement-targeted therapeutics |
| Q37872442 | Complement in the brain. |
| Q48701858 | Comprehensive immunohistochemical studies on canine necrotizing meningoencephalitis (NME), necrotizing leukoencephalitis (NLE), and granulomatous meningoencephalomyelitis (GME). |
| Q37830017 | Current concepts in the neuropathology and pathogenesis of multiple sclerosis |
| Q35592803 | Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication |
| Q36236791 | Demyelination patterns in a mathematical model of multiple sclerosis. |
| Q37267155 | Development of a high-resolution fat and CSF-suppressed optic nerve DTI protocol at 3T: application in multiple sclerosis. |
| Q37328280 | Disease-modifying agents for multiple sclerosis: recent advances and future prospects |
| Q38049628 | Disease-specific therapy of idiopathic inflammatory demyelinating disorders |
| Q91621534 | Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica |
| Q45952606 | Disturbed function of the blood-cerebrospinal fluid barrier aggravates neuro-inflammation. |
| Q35674181 | Environmental pathways to autoimmune diseases: the cases of primary biliary cirrhosis and multiple sclerosis |
| Q39695167 | FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. |
| Q38837294 | Further understanding of the immunopathology of multiple sclerosis: impact on future treatments |
| Q50945427 | Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis. |
| Q41295973 | Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. |
| Q34893931 | Heterogeneity versus homogeneity of multiple sclerosis |
| Q26747682 | High-throughput sequencing of immune repertoires in multiple sclerosis |
| Q39802246 | Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future |
| Q36281698 | IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis |
| Q94475279 | IgG3 + B cells are associated with the development of multiple sclerosis |
| Q28084625 | Imaging neuroinflammation in multiple sclerosis using TSPO-PET |
| Q30620892 | Imaging outcomes for trials of remyelination in multiple sclerosis |
| Q37610907 | Immune characteristics study of AG490, a signal pathway inhibitor, in EAE model mice |
| Q37855723 | Immunologic aspects of multiple sclerosis |
| Q36198757 | Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease? |
| Q93020385 | Impact of B cells to the pathophysiology of multiple sclerosis |
| Q33740931 | Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination. |
| Q36147149 | Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination |
| Q38805611 | Inherited and acquired disorders of myelin: The underlying myelin pathology |
| Q38120744 | Innate immunity and neuroinflammation |
| Q35785935 | Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. |
| Q27496011 | Is Multiple Sclerosis an Autoimmune Disease? |
| Q92173318 | Lupus serum IgG induces microglia activation through Fc fragment dependent way and modulated by B-cell activating factor |
| Q36722852 | Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status |
| Q37301528 | Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype |
| Q37599583 | Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis |
| Q38182524 | Mechanisms of white matter damage in multiple sclerosis |
| Q26997385 | Membrane attack by complement: the assembly and biology of terminal complement complexes |
| Q37119854 | Modeling the heterogeneity of multiple sclerosis in animals |
| Q37033330 | Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease |
| Q60921674 | Multiple Sclerosis: Destruction and Regeneration of Astrocytes in Acute Lesions |
| Q28299151 | Multiple sclerosis |
| Q38254152 | Multiple sclerosis and the role of immune cells. |
| Q82216182 | Multiple sclerosis as an “Inside‐out” disease |
| Q37772077 | Multiple sclerosis genetics--is the glass half full, or half empty? |
| Q21558407 | Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone |
| Q52093620 | Multiple sclerosis: Serum anti-CNS autoantibodies. |
| Q38079620 | Multiple sclerosis: individualized disease susceptibility and therapy response. |
| Q37372509 | Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. |
| Q89830634 | Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides |
| Q34714271 | Oligodendrocyte progenitor cells proliferate and survive in an immature state following treatment with an axolemma-enriched fraction |
| Q38029278 | Oligodendrocytes and the early multiple sclerosis lesion |
| Q33804184 | Pathologic heterogeneity persists in early active multiple sclerosis lesions |
| Q39429415 | Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis |
| Q28270799 | Potassium channel KIR4.1 as an immune target in multiple sclerosis |
| Q35861951 | Preferential Recruitment of Neutrophils into the Cerebellum and Brainstem Contributes to the Atypical Experimental Autoimmune Encephalomyelitis Phenotype |
| Q50021192 | Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis |
| Q40757812 | Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis |
| Q38203770 | Relapsing and progressive forms of multiple sclerosis: insights from pathology |
| Q37893199 | Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis |
| Q39004244 | Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target |
| Q34555203 | Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis |
| Q39152405 | Sulfocerebrosides upregulate liposome uptake in human astrocytes without inducing a proinflammatory response |
| Q36761844 | Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges |
| Q33556336 | Texture analysis: a review of neurologic MR imaging applications |
| Q26776542 | The Ins and Outs of B Cells in Multiple Sclerosis |
| Q38880764 | The Molecular Mechanisms of Vitamin A Deficiency in Multiple Sclerosis. |
| Q36099150 | The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients |
| Q47715259 | The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis |
| Q48445988 | The cuprizone model: regional heterogeneity of pathology |
| Q35155753 | The double-edged sword of autoimmunity: lessons from multiple sclerosis |
| Q38175970 | The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases |
| Q37993033 | The evidence for a role of B cells in multiple sclerosis |
| Q36831144 | The evidence for hypoperfusion as a factor in multiple sclerosis lesion development |
| Q38105468 | The immune pathogenesis of multiple sclerosis. |
| Q26823691 | The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS) |
| Q37857982 | The immunopathophysiology of multiple sclerosis |
| Q34188436 | The neuropathological basis of clinical progression in multiple sclerosis |
| Q37603085 | The pathological spectrum of CNS inflammatory demyelinating diseases |
| Q59339809 | The physiology of foamy phagocytes in multiple sclerosis |
| Q57261975 | The release of cytokines by macrophages is not affected by myelin ingestion |
| Q92302527 | The role of B cells in multiple sclerosis: Current and future therapies |
| Q34468304 | The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. |
| Q38001792 | The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy? |
| Q40134939 | Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis |
| Q37398059 | Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis |
| Q57001708 | Viruses and multiple sclerosis |
Search more.